Back to top
more

Coherus BioSciences (CHRS)

(Delayed Data from NSDQ)

$1.39 USD

1.39
1,537,716

+0.07 (5.30%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

Coherus BioSciences (CHRS) Upgraded to Strong Buy: Here's Why

Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

Is (CHRS) Outperforming Other Medical Stocks This Year?

Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status

The FDA grants fast track status to Arena's (ARNA) early-stage candidate, APD418, for the treatment of decompensated heart failure.

Amarin Posts '19 Preliminary Results, Gives 2020 Expense View

Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.

Is Coherus BioSciences (CHRS) Stock Outpacing Its Medical Peers This Year?

Is (CHRS) Outperforming Other Medical Stocks This Year?

Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder

Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.

Pulmatrix Surges on License Agreement With Johnson & Johnson

Pulmatrix (PULM) inks an agreement with an entity of J&J, granting it the license to develop a portfolio of narrow spectrum kinase inhibitors for lung cancer interception.

Arena (ARNA) Expands Strategic Deal With Beacon Discovery

Arena (ARNA) enters into multi-year strategic partnership with Beacon Discovery to discover and develop therapies targeting multiple immune and inflammatory indications.

Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

Has Coherus BioSciences (CHRS) Outpaced Other Medical Stocks This Year?

Is (CHRS) Outperforming Other Medical Stocks This Year?

5 Biotech Stocks Set for Continued Rally in 2020

The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.

Top Ranked Momentum Stocks to Buy for December 3rd

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 3rd

Top Ranked Momentum Stocks to Buy for November 26th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 26th

Alkermes to Acquire Rodin Therapeutics, Boost CNS Pipeline

Alkermes (ALKS) will acquire Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in milestone payments.

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene

4 Biotech Stocks That Could Keep Beating Wall Street

The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

Coherus BioSciences (CHRS) Q3 Earnings and Revenues Surpass Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Benjamin Rains headshot

Investors Can Find Strong Stocks with our First Profit Screen

Today, we are utilizing our 'First Profit' stock screen to help investors find strong stocks. The idea is to search for companies that just reported their first quarterly profit within the last year...

Coherus BioSciences (CHRS) Upgraded to Buy: Here's What You Should Know

Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Benjamin Rains headshot

Investors Can Find Big Returns with this First Profit Screen

We are taking a look at our 'First Profit' stock screen today. The idea is to search for companies that just reported their first quarterly profit within the last year because these firms could prove to be big winners for investors...

Coherus BioSciences (CHRS) Beats Q2 Earnings and Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Top Ranked Momentum Stocks to Buy for July 12th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 12th